Roth Capital Forecasts Nuwellis’ Q2 Earnings (NASDAQ:NUWE)

Nuwellis, Inc. (NASDAQ:NUWE) – Research analysts at Roth Capital decreased their Q2 2025 earnings per share estimates for shares of Nuwellis in a report issued on Tuesday, May 13th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($0.45) for the quarter, down from their previous forecast of ($0.36). Roth Capital currently has a “Buy” rating on the stock. The consensus estimate for Nuwellis’ current full-year earnings is ($8.17) per share. Roth Capital also issued estimates for Nuwellis’ Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $1.42 EPS.

Nuwellis Price Performance

Shares of Nuwellis stock opened at $0.94 on Friday. Nuwellis has a 1 year low of $0.75 and a 1 year high of $11.66. The firm has a market cap of $4.11 million, a PE ratio of -0.01 and a beta of 0.51. The stock has a fifty day moving average price of $0.97 and a 200-day moving average price of $1.19.

Nuwellis (NASDAQ:NUWE) last announced its earnings results on Tuesday, May 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.24). Nuwellis had a negative net margin of 169.54% and a negative return on equity of 28,159.25%. The business had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $2.50 million.

Institutional Investors Weigh In On Nuwellis

An institutional investor recently bought a new position in Nuwellis stock. Virtu Financial LLC acquired a new position in Nuwellis, Inc. (NASDAQ:NUWE) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 27,080 shares of the company’s stock, valued at approximately $25,000. Virtu Financial LLC owned about 0.62% of Nuwellis as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 3.13% of the company’s stock.

About Nuwellis

Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.